Samsung Electronics has announced that the Irregular Heart Rhythm Notification (IHRN) feature in its Samsung Health Monitor app has received clearance from the US Food and Drug Administration (FDA). The IHRN feature, in combination with the app’s existing Electrocardiogram (ECG) function, enables users to monitor heart rhythms that could indicate atrial fibrillation (AFib), one of the leading warning signs of major cardiovascular issues.

AFib is sometimes asymptomatic or silent, meaning people may not be aware of their risk. Samsung’s Galaxy Watch offers users tools to monitor their heart health using the Samsung BioActive Sensor, including on-demand ECG recording and an HR Alert function that detects abnormally high or low heart rates. The new IHRN feature adds another aspect to the monitoring capabilities of the watch.